MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dynavax Technologies Company Profile (NASDAQ:DVAX)

Consensus Ratings for Dynavax Technologies (NASDAQ:DVAX) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $35.25 (154.15% upside)

Analysts' Ratings History for Dynavax Technologies (NASDAQ:DVAX)
Show:
DateFirmActionRatingPrice TargetActions
4/28/2016Cowen and CompanyReiterated RatingBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2016RBC CapitalDowngradeOutperform -> Sector Perform$48.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/27/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$29.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2015William BlairReiterated RatingOutperform$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Dynavax Technologies (NASDAQ:DVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.95)($0.97)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($1.06)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.06)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dynavax Technologies (NASDAQ:DVAX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.52)($0.52)($0.52)
Q2 20161($0.68)($0.68)($0.68)
Q3 20161($0.68)($0.68)($0.68)
Q4 20161($0.72)($0.72)($0.72)
(Data provided by Zacks Investment Research)
Dividend History for Dynavax Technologies (NASDAQ:DVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dynavax Technologies (NASDAQ:DVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Dynavax Technologies (NASDAQ:DVAX)
DateHeadline
06/24/16 10:28 AMCovering the Bases on Dynavax Technologies Corporation (NASDAQ:DVAX): Where is the Stock Going? - Press Telegraph
06/23/16 02:39 PMCan Dynavax Technologies Corporation (NASDAQ:DVAX) Surprise Analysts this Quarter? - Investor Newswire
06/23/16 07:18 AMDynavax Technologies Corporation (DVAX) Current Analyst Ratings - Fiscal Standard
06/21/16 03:30 PMDynavax Technologies Corporation (NasdaqCM:DVAX) Stock Momentum Hits Extreme Weakness - CML News
06/20/16 03:37 PMCompany Shares of Dynavax Technologies Corporation Drops by -2.19% - Trade Calls
06/15/16 03:46 PMDynavax's HEPLISAV-B beats Glaxo's ENGERIX-B in late-stage study - Seeking Alpha
06/15/16 03:46 PMBiotech Forum Daily Digest: Heading Down; Valeant's Plan; What I Am Buying Now - Seeking Alpha
06/15/16 08:29 AMForm 8-K DYNAVAX TECHNOLOGIES For: Jun 11 - StreetInsider.com
06/12/16 11:29 PM12:29 am Dynavax reports Phase 3 data for HEPLISAV-B showing significantly higher rate of seroprotection than an approved vaccine in patients with Type 2 Diabetes -
06/12/16 03:38 PMDynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA ... - Marketwired (press release)
06/12/16 08:28 AMDynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B™, in Adults With Type 2 Diabetes at ADA Scientific Sessions
06/11/16 10:19 AMDynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions - [at noodls] - BERKELEY, CA -- (Marketwired) -- 06/11/16 -- Dynavax Technologies Corporation(NASDAQ: DVAX)today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, ...
06/11/16 08:34 AMDynavax Technologies Corporation (DVAX) Drops 6.87% on June 09 - Equities.com
06/10/16 08:37 AMCoverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and ... - PR Newswire (press release)
06/08/16 02:39 PMStock upgrade: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Dynavax Technologies Corporation (NASDAQ:DVAX ... - KC Register
06/08/16 02:39 PMDynavax Technologies Corporation (NASDAQ:DVAX) decreased -2.32%: Repligen Corporation (NASDAQ:RGEN ... - KC Register
06/04/16 03:43 PMWill Dynavax Technologies Corporation (NASDAQ:DVAX) Surprise Analysts? - Investor Newswire
06/04/16 08:55 AMReview of Analysts Ranking: Insulet Corporation (NASDAQ:PODD) , Dynavax Technologies Corporation (NASDAQ ... - Street Updates
06/03/16 09:27 AMShare Rating Focus on Dynavax Technologies Corporation (NASDAQ:DVAX) - HNN
06/02/16 08:31 AMTarget Price and Stock Performance Rundown for Dynavax Technologies Corporation (NASDAQ:DVAX) - HNN - Target Price and Stock Performance Rundown for Dynavax Technologies Corporation (NASDAQ:DVAX)HNNA commonly used metric is a the P/E ratio of the company. This calculation stems from dividing the current share price by the projected earnings per share. Dynavax Technologies Corporatio currently has a price to earnings ratio of N/A. Analysts and ...and more »
06/01/16 03:54 PMStrong Sell Calls Count For Dynavax Technologies Corporation (NASDAQ:DVAX) At 0 - Investor Newswire - Strong Sell Calls Count For Dynavax Technologies Corporation (NASDAQ:DVAX) At 0Investor NewswireDynavax Technologies Corporation (NASDAQ:DVAX) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-05-31. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
06/01/16 03:54 PMBuy, Sell Or Hold Rating For Dynavax Technologies Corporation (DVAX)? - Share Trading News - Buy, Sell Or Hold Rating For Dynavax Technologies Corporation (DVAX)?Share Trading News12/01/2014 – Dynavax Technologies Corporation had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 25 price target on the stock. Dynavax Technologies Corporation has a 50 day moving average of 17.55 and a 200 day moving ...Analyst Review: Dynavax Technologies Corporation (DVAX)Risers & Fallersall 5 news articles »
05/31/16 03:49 PM2 Small Attractive Biotech Stocks With Recent Insider Buying - Seeking Alpha - Seeking Alpha2 Small Attractive Biotech Stocks With Recent Insider BuyingSeeking AlphaThe biotech sector seems to be slowly moving out of its longest and deepest bear markets in memory. A pick up in M&A activity is certain helping. It also seems that there has been uptick in insider buying in many of the smaller biotech holdings within ...and more »
05/31/16 03:29 PMDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/27/16 07:50 PMDynavax Technologies Corporation (NASDAQ:DVAX) Closes At $15.850 - Investor Newswire - Dynavax Technologies Corporation (NASDAQ:DVAX) Closes At $15.850Investor NewswireDynavax Technologies Corporation (NASDAQ:DVAX), a NCM public traded company has 36382000 shares floating. Its outstanding shares count is 38495000 bringing market capitalization to $608.41M. In the last session, Dynavax Technologies Corporation ...and more »
05/26/16 02:38 PMTraders Checklist Stocks: Oncothyreon Inc. (NASDAQ:ONTY) , Dynavax Technologies Corporation (NASDAQ:DVAX) , - Street Updates - Traders Checklist Stocks: Oncothyreon Inc. (NASDAQ:ONTY) , Dynavax Technologies Corporation (NASDAQ:DVAX) ,Street UpdatesOn 5/25/2016, shares of Oncothyreon Inc. (NASDAQ:ONTY) rose +3.54% in trading session and finally closed at $1.17. The company most recent volume stood at 974.84 thousand shares as compared to its average volume of 934.17 thousand shares.Big Movers: MacroGenics, Inc. (NASDAQ:MGNX), Dynavax Technologies Corporation (NASDAQ:DVAX), Curis, Inc ...Benchmark MonitorDynavax Technologies Corporation (NASDAQ:DVAX) Earnings Preview: Should Investors Be Nervous?iStreetWireall 4 news articles »
05/23/16 02:36 PM19 Biotechnology Stocks to Sell Now - Investorplace.com - 19 Biotechnology Stocks to Sell NowInvestorplace.comDynavax Technologies Corporation discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The company also gets F's in sales growth, earnings surprise, return on equity, and free ...and more »
05/22/16 07:34 PMDynavax Technologies Corporation (DVAX) Broker Price Targets For The Coming Week - Share Trading News - Dynavax Technologies Corporation (DVAX) Broker Price Targets For The Coming WeekShare Trading News12/01/2014 – Dynavax Technologies Corporation had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 25 price target on the stock. Dynavax Technologies Corporation has a 50 day moving average of 18.52 and a 200 day moving ...Alpha One Assigns Impact Score Of 50 To Dynavax Technologies Corporation (NASDAQ:DVAX)Enterprise LeaderDynavax Technologies Corporation (NASDAQ:DVAX) Reports Basic Consolidated EPS At $-3.2479Equities Focusall 9 news articles »
05/22/16 02:26 PMDynavax Technologies Corporation (DVAX) Updated Broker Price Targets - Share Trading News - Dynavax Technologies Corporation (DVAX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Dynavax Technologies Corporation (DVAX). The latest reports which are currently in issue on Friday 20th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...Latest Price movements of Stocks: Dynavax Technologies Corporation (NASDAQ:DVAX) , Venaxis, Inc. (NASDAQ:APPY)Street UpdatesDynavax Technologies Corporation (NASDAQ:DVAX) Hovering Around $15.21RealistInvestor.comall 3 news articles »
05/20/16 02:36 PMAnalyst Rating Check on Dynavax Technologies Corporation (NASDAQ:DVAX) - Wall Street Hints and News - Analyst Rating Check on Dynavax Technologies Corporation (NASDAQ:DVAX)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 2 on shares of Dynavax Technologies Corporation (NASDAQ:DVAX). Analysts that cover the ...and more »
05/19/16 06:18 PMETF’s with exposure to Dynavax Technologies Corp. : May 19, 2016 -
05/18/16 07:39 PMRevenue Update on Dynavax Technologies Corporation(NASDAQ:DVAX) - Trade Calls - Revenue Update on Dynavax Technologies Corporation(NASDAQ:DVAX)Trade CallsDynavax Technologies Corporation(NASDAQ:DVAX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $942.00K. Analysts estimated a revenue of $1.10M.
05/18/16 12:04 PMDYNAVAX TECHNOLOGIES CORP Financials -
05/18/16 06:42 AMDynavax to Present at Two Upcoming Investor Conferences - [at noodls] - BERKELEY, CA -- (Marketwired) -- 05/18/16 -- Dynavax Technologies Corporation(NASDAQ: DVAX)today announced that it will present at two upcoming investor conferences. Information relating to the two presentations ...
05/17/16 01:30 PMDynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 07:32 AMStocks within Investors Screening: Dynavax Technologies Corporation (NASDAQ:DVAX) , Eleven Biotherapeutics, Inc ... - Street Updates - Stocks within Investors Screening: Dynavax Technologies Corporation (NASDAQ:DVAX) , Eleven Biotherapeutics, Inc ...Street UpdatesOn 5/13/2016, shares of Dynavax Technologies Corporation (NASDAQ:DVAX) rose +5.18% in trading session and finally closed at $15.22. The company most recent volume stood at 669.36 thousand shares as compared to its average volume of 931.92 ...Dynavax Technologies Corporation (DVAX) Broker Price Targets For The Coming WeekShare Trading NewsDynavax Tech Corporation (NASDAQ:DVAX) Shorts Decreased by 0.03% After Short CoveringThe PostDynavax Technologies Corporation (NASDAQ:DVAX) Basic Consolidated EPS At $-3.2479Equities FocusEnterprise Leaderall 5 news articles »
05/15/16 02:47 PMJanssen Robert, Vice President of Dynavax Technologies Corporatio (NASDAQ:DVAX) buys 1,000 shares - According to Dynavax Technologies Corporatio's most recent Form 4 filing with the SEC dated May 13 09:30 AM, company Vice President ... trades made by Dynavax Technologies Corporatio (NASDAQ:DVAX) Vice President, Janssen Robert, we have the following ...
05/14/16 01:00 AMDynavax Technologies Corp (DVAX) Jumps 5.18% on May 13 - Equities.com - Dynavax Technologies Corp (DVAX) Jumps 5.18% on May 13Equities.comDynavax Technologies Corp (DVAX) was among the biggest gainers on the Russell 2000 for Friday May 13 as the stock popped 5.18% to $15.22, representing a gain of $0.75 per share. Some 652,750 shares traded hands on 5,983 trades, compared with an ...and more »
05/11/16 02:47 PMBrokerages Anticipate Dynavax Technologies Co. (NASDAQ:DVAX) to Announce ($0.55) EPS - Washington News Wire - Washington News WireBrokerages Anticipate Dynavax Technologies Co. (NASDAQ:DVAX) to Announce ($0.55) EPSWashington News WireDynavax Technologies Co. (NASDAQ:DVAX) has been given an average broker rating score of 0.00 () from the zero brokers that provide coverage for the stock, Zacks Investment Research reports. DVAX has been the topic of a number of recent research ...Dynavax Technologies Co. (DVAX) Upgraded to "Hold" by Zacks Investment ResearchWeb Breaking NewsTake a look at Price Fluctuations: Unilife Corporation (NASDAQ:UNIS) , Dynavax Technologies Corporation (NASDAQ ...Street Updatesall 6 news articles »
05/10/16 02:44 PMPerilous Reversal Stock: Dynavax Technologies (DVAX) - TheStreet.com - share market updates (press release)Perilous Reversal Stock: Dynavax Technologies (DVAX)TheStreet.comCompared to other companies in the Biotechnology industry and the overall market, DYNAVAX TECHNOLOGIES CORP's return on equity significantly trails that of both the industry average and the S&P 500. DVAX, with its very weak revenue results, has ...Dynavax Tech Corporation (NASDAQ:DVAX) Shorted Shares Increased By 2.77%Franklin IndependentHC Sector Updates: Dynavax Technologies Corporation (DVAX), IDEXX Laboratories Inc. (IDXX), aTyr Pharma Inc (LIFE)share market updates (press release)Dynavax Technologies Corp (DVAX) Jumps 6.96% on May 09Equities.comNews Tribune -B.O.D.Y Confidentialall 5 news articles »
05/10/16 12:58 AMDynavax Technologies Corp (DVAX) Jumps 6.96% on May 09 - Equities.com - Dynavax Technologies Corp (DVAX) Jumps 6.96% on May 09Equities.comDynavax Technologies Corp (DVAX) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 6.96% to $15.07, representing a gain of $0.98 per share. Some 883,565 shares traded hands on 7,283 trades, compared with ...
05/09/16 05:10 PMDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/09/16 05:04 PMDYNAVAX TECHNOLOGIES CORP Files SEC form 10-Q, Quarterly Report -
05/09/16 08:08 AMDynavax Reports First Quarter 2016 Financial Results - [at noodls] - BERKELEY, CA -- (Marketwired) -- 05/09/16 -- Dynavax Technologies Corporation(NASDAQ: DVAX)today reported financial results for the first quarter ended March 31, 2016. The Company had $166.8 million in ...
05/09/16 08:05 AMDynavax Technologies reports 1Q loss -
05/08/16 07:53 PMDynavax Technologies: An Updated View After FDA Decision - Dynavax Technologies Corporation is a small clinical-stage biopharmaceutical company with multiple product candidates ... Disclosure: I am/we are long DVAX, RLYP. I wrote this article myself, and it expresses my own opinions. I am not receiving ...
05/08/16 02:46 PMDynavax Technologies: An Updated View After FDA Decision - Seeking Alpha - Seeking AlphaDynavax Technologies: An Updated View After FDA DecisionSeeking AlphaIt has not been the best of times for small biotech concern Dynavax Technologies (NASDAQ:DVAX). The stock has been hammered since the FDA pushed back the PDUFA date for its ... Dynavax Technologies Corporation is a small clinical-stage ...
05/07/16 07:47 PMAnalysts Reviewing Stocks: PDL BioPharma, Inc. (NASDAQ:PDLI) , Dynavax Technologies Corporation (NASDAQ:DVAX) - Street Updates - Analysts Reviewing Stocks: PDL BioPharma, Inc. (NASDAQ:PDLI) , Dynavax Technologies Corporation (NASDAQ:DVAX)Street UpdatesDynavax Technologies Corporation (NASDAQ:DVAX) moved in red zone with decline of -0.29 points or -2.02% to $14.09. The company has a market worth of $541.41M.Total 880.23 thousand shares were exchanged in last trading session as opposed to ...
05/06/16 02:45 PMDynavax Technologies Corp (DVAX) Hits New 52-week Low During May 04 Session - Equities.com - Dynavax Technologies Corp (DVAX) Hits New 52-week Low During May 04 SessionEquities.comDynavax Technologies Corp (DVAX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $15.98, Dynavax Technologies Corp dropped to $14.68 for a new 52-week low. By the closing bell, the company's ...and more »
04/27/16 03:19 PMDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
About Dynavax Technologies

Dynavax Technologies logoDynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DVAX
  • CUSIP: 26815810
Key Metrics:
  • Previous Close: $13.87
  • 50 Day Moving Average: $15.34
  • 200 Day Moving Average: $19.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $533.93M
  • Current Quarter EPS Consensus Estimate: $-2.90 EPS
Additional Links:
Dynavax Technologies (NASDAQ:DVAX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha